Yesterday, Jan. 7, 2016, 46 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $4.10 to $4,184,386.80.

Highlighted Stocks Traded by Insiders:

Smith & Wesson (SWHC) - FREE Research Report

Scott Robert L, who is Director at Smith & Wesson, sold 40,000 shares at $26.02 on Jan. 7, 2016. Following this transaction, the Director owned 64,336 shares meaning that the stake was reduced by 38.34% with the 40,000-share transaction.

Brust Robert H, who is Director at Smith & Wesson, sold 17,534 shares at $24.59 on Jan. 7, 2016. Following this transaction, the Director owned 3,802 shares meaning that the stake was reduced by 82.18% with the 17,534-share transaction.

The shares most recently traded at $23.82, down $0.77, or 3.24% since the insider transaction. Historical insider transactions for Smith & Wesson go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 55,928
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 55,928
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 87,993

The average volume for Smith & Wesson has been 1.9 million shares per day over the past 30 days. Smith & Wesson has a market cap of $1.3 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 7.42% year-to-date as of the close of trading on Thursday.

Smith & Wesson Holding Corporation manufactures and sells firearm products in the United States and internationally. The company operates in two segments, firearms and accessories. The company has a P/E ratio of 24.0. Currently, there are 6 analysts who rate Smith & Wesson a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWHC - FREE

TheStreet Quant Ratings rates Smith & Wesson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Wesson Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Republic Airways Holdings (RJET) - FREE Research Report

Willman Ryan, who is VP, Corporate Controller at Republic Airways Holdings, sold 6,108 shares at $3.25 on Jan. 7, 2016. Following this transaction, the VP, Corporate Controller owned 20,200 shares meaning that the stake was reduced by 23.22% with the 6,108-share transaction.

The shares most recently traded at $2.35, down $0.90, or 38.3% since the insider transaction. Historical insider transactions for Republic Airways Holdings go as follows:

  • 4-Week # shares sold: 3,359
  • 12-Week # shares sold: 3,359
  • 24-Week # shares sold: 3,359

The average volume for Republic Airways Holdings has been 1.3 million shares per day over the past 30 days. Republic Airways Holdings has a market cap of $142.0 million and is part of the services sector and transportation industry. Shares are down 34.61% year-to-date as of the close of trading on Thursday.

Republic Airways Holdings Inc., through its subsidiaries, provides scheduled passenger services. The company offers scheduled passenger service on approximately 1,229 flights daily to approximately 101 cities in the U.S. and Canada. The company has a P/E ratio of 5.6. Currently, there is 1 analyst who rates Republic Airways Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RJET - FREE

TheStreet Quant Ratings rates Republic Airways Holdings as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Republic Airways Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report

Ballinger Kevin J., who is SVP & Pres, Interven Cardio at Boston Scientific, sold 19,059 shares at $17.73 on Jan. 7, 2016. Following this transaction, the SVP & Pres, Interven Cardio owned 30,323 shares meaning that the stake was reduced by 38.6% with the 19,059-share transaction.

The shares most recently traded at $17.64, down $0.09, or 0.48% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 11,700
  • 4-Week # shares sold: 26,067
  • 12-Week # shares bought: 11,700
  • 12-Week # shares sold: 221,346
  • 24-Week # shares bought: 11,700
  • 24-Week # shares sold: 228,259

The average volume for Boston Scientific has been 9.0 million shares per day over the past 30 days. Boston Scientific has a market cap of $24.2 billion and is part of the health care sector and health services industry. Shares are down 4.34% year-to-date as of the close of trading on Thursday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 14 analysts who rate Boston Scientific a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.